| pubmed-article:20028817 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:20028817 | lifeskim:mentions | umls-concept:C0870071 | lld:lifeskim |
| pubmed-article:20028817 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20028817 | pubmed:dateCreated | 2010-2-22 | lld:pubmed |
| pubmed-article:20028817 | pubmed:abstractText | Recombinant alpha interferon (IFN-alpha) is used in the treatment of hepatitis C virus (HCV)-infected patients but is not optimal in terms of efficacy or tolerability. Toll-like 7 receptor (TLR-7) agonists stimulate the innate immune system to produce, among other cytokines, IFN-alpha and are being evaluated as alternative drugs to treat HCV infection. This paper describes the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling to understanding the behavior of a TLR-7 agonist [9-benzyl-8-hydroxy-2-(2-methoxyethoxy) adenine (BHMA)] in mice, using IFN-alpha as a biomarker. This is the first report of such a PK-PD model, and the conclusions may be of utility in the clinical development of TLR-7 agonists for HCV infection. | lld:pubmed |
| pubmed-article:20028817 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20028817 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20028817 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20028817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20028817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20028817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20028817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20028817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20028817 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20028817 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:20028817 | pubmed:issn | 1098-6596 | lld:pubmed |
| pubmed-article:20028817 | pubmed:author | pubmed-author:JonesHannah... | lld:pubmed |
| pubmed-article:20028817 | pubmed:author | pubmed-author:Van der... | lld:pubmed |
| pubmed-article:20028817 | pubmed:author | pubmed-author:BensonNeilN | lld:pubmed |
| pubmed-article:20028817 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:20028817 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:20028817 | pubmed:author | pubmed-author:DuckworthJona... | lld:pubmed |
| pubmed-article:20028817 | pubmed:author | pubmed-author:PertinezHenry... | lld:pubmed |
| pubmed-article:20028817 | pubmed:author | pubmed-author:RawalJaiessh... | lld:pubmed |
| pubmed-article:20028817 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20028817 | pubmed:volume | 54 | lld:pubmed |
| pubmed-article:20028817 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20028817 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20028817 | pubmed:pagination | 1179-85 | lld:pubmed |
| pubmed-article:20028817 | pubmed:dateRevised | 2010-9-2 | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:meshHeading | pubmed-meshheading:20028817... | lld:pubmed |
| pubmed-article:20028817 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20028817 | pubmed:articleTitle | Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice. | lld:pubmed |
| pubmed-article:20028817 | pubmed:affiliation | Department of Pharmacokinetics, Pharmacodynamics and Metabolism, Pfizer Global Research and Development, Ramsgate Road, Sandwich, United Kingdom. neil.benson@pfizer.com | lld:pubmed |
| pubmed-article:20028817 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20028817 | lld:chembl |
